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Abstract In HIV-1 infection, a population of latently infected cells facilitates viral persistence 
despite antiretroviral therapy (ART). With the aim of identifying individuals in whom ART might 
induce a period of viraemic control on stopping therapy, we hypothesised that quantification of the 
pool of latently infected cells in primary HIV-1 infection (PHI) would predict clinical progression and 
viral replication following ART. We measured HIV-1 DNA in a highly characterised randomised 
population of individuals with PHI. We explored associations between HIV-1 DNA and immunological 
and virological markers of clinical progression, including viral rebound in those interrupting therapy. 
In multivariable analyses, HIV-1 DNA was more predictive of disease progression than plasma viral 
load and, at treatment interruption, predicted time to plasma virus rebound. HIV-1 DNA may help 
identify individuals who could safely interrupt ART in future HIV-1 eradication trials.
Clinical trial registration: ISRCTN76742797 and EudraCT2004-000446-20
DOI: 10.7554/eLife.03821.001
Introduction
Renewed interest in exploring avenues for curing Human Immunodeficiency Virus Type 1 (HIV-1) infec-
tion (Henrich et al., 2013; Persaud et al., 2013; Saez-Cirion et al., 2013; Denton et al., 2014; Tebas 
et al., 2014) has resulted in the investigation of interventions to eradicate cells in which HIV-1 persists 
despite antiretroviral therapy (ART). Once HIV-1 has infected a cell and integrated its genome into the 
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cellular DNA, that cell may revert to a resting state, only producing replication competent virions when 
activated at a later date. These cells have been labeled the ‘HIV reservoir’. There is, however, a lack of 
clarity relating to the cell types that might harbour the ‘reservoir’, as well as the tissues in which these cells 
might be located. For clarity, we will use the term ‘reservoir’ to describe the population of HIV-1-infected 
cells that persist during ART and which are the source of rebound viraemia on stopping therapy. Current 
understanding is that the majority of cells comprising this reservoir are CD4 T memory cells of a resting 
phenotype (Avettand-Fenoel et al., 2009; Liszewski et al., 2009; Eriksson et al., 2013).
Many assays have been developed to quantify the HIV-1 reservoir, ranging from simple quantita-
tive PCR (qPCR) estimation of cell associated HIV-1 DNA to labour-intensive viral outgrowth assays 
(VOA) (Siliciano and Siliciano, 2005; Avettand-Fenoel et al., 2009; Liszewski et al., 2009; Eriksson 
et al., 2013). Whereas measurement of plasma viraemia (‘viral load’) and CD4 T cell count are docu-
mented surrogate markers of HIV clinical progression, the clinical relevance and utility of measuring 
the reservoir—regardless of assay–remains less clear. As cell-associated HIV-1 DNA precedes plasma 
viraemia in the viral life cycle, it is tantalizing to speculate whether measuring HIV-1 DNA (as a surro-
gate for reservoir size) might have significant clinical relevance.
It is well documented that HIV-1 DNA persists in patients on antiretroviral therapy (ART) even when 
the plasma viral load is undetectable using the most sensitive assays (Palmer et al., 2008; Saez-Cirion 
et al., 2013). Much of this detectable HIV-1 DNA has been found to be mutated and replication-
incompetent calling into question its biological relevance (Ho et al., 2013). However, as a simple 
eLife digest HIV is a virus that can hide in, and hijack, the cells of the immune system and force 
them to make new copies of the virus. This eventually destroys the infected cells and weakens the 
ability of a person with HIV to fight off infections and disease. If diagnosed early and treated, most 
people with HIV now live long and healthy lives and do not develop AIDS—the last stage of HIV 
infection when previously harmless, opportunistic infections can become life-threatening. However, 
there are still numerous hurdles and challenges that must be overcome before a cure for HIV/AIDS 
can be developed.
Treatment with drugs called antiretrovirals can reduce the amount of the HIV virus circulating in 
an infected person's bloodstream to undetectable levels. However, when HIV infects a cell, the  
virus inserts a copy of its genetic material into the cell's DNA—and, for most patients, antiretroviral 
treatment does not tackle these ‘hidden viruses’. As such, and in spite of their side-effects, 
antiretroviral drugs have to be taken for life in case the hidden viruses re-emerge.
As research into a cure for HIV/AIDS gathers momentum, patients who might be candidates for 
new experimental treatments will need to be identified. Although it is not recommended as part  
of standard clinical care, the only way to test if a patient's viral levels would remain suppressed 
without the drugs would be to temporarily stop the treatment under the close supervision of a 
physician. As such, a new method is needed to identify if there are patients who might benefit  
from stopping antiretroviral therapy, and more importantly, those who might not.
Williams, Hurst et al. have now tested whether measuring the levels of HIV DNA directly might 
help to predict if, and when, the virus might re-emerge (or rebound). In a group of HIV patients 
participating in a clinical trial, those with higher levels of HIV DNA at the point that the treatment 
was stopped were found to experience faster viral rebound than those with lower levels of HIV 
DNA. This method could therefore identify those patients who are at the greatest risk of HIV viral 
rebound, and are therefore unlikely to benefit if their treatment is interrupted.
Williams, Hurst et al. also found that measuring the levels of HIV DNA could help to predict how 
the disease would progress in treated and untreated patients. Furthermore, these predictions were 
more accurate than those based on measuring the amount of the virus circulating in a patient's body.
The next challenge is to identify other methods to distinguish patients who may remain ‘virus-
free’ for a period without treatment, from those who would not. With this achieved, it might be 
possible to identify the mechanisms that determine why the virus comes back and so develop new 
treatments to stop this happening. This would make developing a cure for HIV/AIDS a much more 
tangible prospect.
DOI: 10.7554/eLife.03821.002
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surrogate measure of the reservoir it may still have a role to play. As new interventions to cure HIV-1 
infection are developed and taken into clinical trials, a means to measure their efficacy is needed. 
Stopping ART to await the return of viraemia would be the ‘gold standard’ approach, but has been 
associated with risk in certain (Strategies for Management of Antiretroviral Therapy (SMART) 
Study Group et al., 2006), although not all studies (SPARTAC Trial Investigators et al., 2013). Ideally, 
the clinician would have access to an algorithm of biomarker assays to help identify those patients 
who might (or, alternatively, should not) be candidates for a safe treatment interruption (TI). The best 
way to assess the patient successfully managed on ART is unclear but, with the viral load rendered 
undetectable, it is plausible that HIV-1 DNA might be an alternative biomarker for disease progression. 
For example, compared with individuals with uncontrolled viraemia, HIV-1 DNA levels are much lower 
in cohorts such as VISCONTI in which apparently persistent aviraemia has been reported following TI 
(Saez-Cirion et al., 2013), and in the case of the Mississippi baby extremely low DNA levels were asso-
ciated with a prolonged period of virological remission. However, this contrasts with cases in which 
undetectable DNA on ART was associated with prompt rebound viraemia on stopping (Chun et al., 
2010; Henrich et al., 2014). We therefore wished to gain a broader picture of the utility of measuring 
HIV-1 DNA levels by studying participants in a large, randomized trial of primary HIV-1 infection.
We measured both Total and Integrated HIV DNA levels in peripheral blood CD4 T cells in partici-
pants in the Short Pulse Antiretroviral Treatment at HIV-1 Seroconversion (SPARTAC) trial (SPARTAC 
Trial Investigators et al., 2013)–the largest randomized clinical trial of short-course ART in primary 
HIV-1 infection (PHI). Studying individuals recruited at PHI, randomized to no treatment or ART, and 
who subsequently underwent treatment interruption, allowed us to ask two questions. Was HIV-1 DNA 
independently predictive of clinical progression, and did HIV-1 DNA predict the time taken for virae-
mic rebound on stopping therapy, advocating its role in future treatment interruption protocols?
Results
SPARTAC trial participant characteristics
154 participants across all the SPARTAC trial arms were studied based on infection with subtype B 
HIV-1 and sample availability. All 154 patients were sampled at the pre-therapy baseline at trial enrol-
ment. The demographics of the 154 participants are shown in Table 1. Participants who were ran-
domised to receive no therapy or 48 weeks of ART and for whom samples were available (n = 51 and 
n = 47, respectively; Supplementary file 1) were studied in separate analyses described below. 
Assays of both Total and Integrated HIV-1 DNA were conducted at pre-therapy ‘baseline’ (trial week 0) 
and then at weeks 12, 48, 52, 60 and 108, where samples permitted. As detailed in Supplementary 
file 2, not all patients were assayed at all time-points, dependent on the analyses being conducted 
and sample availability.
Pre-ART HIV-1 DNA associates with surrogate markers of disease 
progression
Traditionally, plasma viral load (VL) (Mellors et al., 1996) and CD4 cell count (Frater et al., 2014) are 
the only validated surrogate markers of progression used in the HIV-1 clinic. We therefore measured 
these biomarkers as well as HIV-1 DNA in 154 SPARTAC participants at enrolment to the trial and prior 
to any ART being given. The median (interquartile range) values of Total and Integrated HIV-1 DNA 
values in PHI (Figure 1—figure supplement 1) were 7707 (2477–18187) and 3830 (1563–6325) copies 
of HIV-1 DNA per million CD4 T cells, respectively. Total and Integrated HIV-1 DNA levels were 
closely associated (p < 0.0001; r2 = 0.72; Pearson correlation) (Figure 1—figure supplement 2) in 
these pre-therapy samples. Total and Integrated HIV-1 DNA were significantly associated with plasma 
viral load (both p < 0.001; r2 = 0.48 and 0.64, respectively; linear regression) (Figure 1A), and inversely 
with CD4 T cell count (both p < 0.001; r2 = 0.20 and 0.27, respectively; linear regression) (Figure 1B). 
Interestingly, the estimated time since seroconversion at recruitment did not correlate with HIV-1 DNA 
(both Integrated and Total) (Figure 1—figure supplement 3).
HIV-1 DNA in untreated patients predicts disease progression
For this analysis, disease progression was defined according to the primary end-point of the SPARTAC 
trial, that is, a composite end-point of either a CD4 T cell count of 350 cells/µl or the commencement 
of long-term ART (for any clinical determined decision) (SPARTAC Trial Investigators et al., 2013). We 
carried out Kaplan–Meier survival analyses with patients randomised to receive no ART, and stratified 
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according to median HIV-1 DNA level at time of 
recruitment (n = 51 for Total HIV-1 DNA, and n = 38 
for Integrated [due to limited sample availability]) 
(patient demographics detailed in Supplementary 
file 1). There was a significant delay in clinical pro-
gression in those with lower Total and Integrated 
HIV-1 DNA at baseline (p = 0.0016 and 0.0022, 
respectively; log-rank test) (Figure 2). The median 
time from randomization to primary endpoint 
stratified by low and high Total HIV-1 DNA levels 
was 187.0 (IQR 127.0–222.0) and 77.9 (IQR 35.0–
172.8) weeks, respectively, and for low and high 
Integrated levels was 187.7 (IQR 132.7–214.9) and 
52.0 (IQR 32.4–161.3) weeks, respectively.
Univariable Cox analyses showed Total HIV-1 
DNA (HR 4.16 per log10 increase [CI 2.10–8.26]; 
p < 0.0001), Integrated HIV-1 DNA (HR 5.41 per 
log10 increase (CI 1.65–18.04); p = 0.006) and 
plasma viral load (HR 1.74 per log10 increase 
(CI 1.13–2.68) p = 0.011) predicted the trial pri-
mary endpoint (Table 2). Multivariable analyses 
were carried out with the baseline covariates, 
Total HIV-1 DNA, viral load, and CD4 T cell count. 
Here, Total HIV-1 DNA (HR = 3.57 (1.58–8.08); 
p = 0.002) and CD4 count (HR = 0.67 (0.53–0.84); 
p < 0.001), but not plasma viral load (HR = 1.25 
(0.80–1.95); p = 0.33) predicted time to primary 
endpoint (Table 2). In a similar multivariable anal-
ysis, Integrated DNA did not associate signifi-
cantly with the trial endpoint.
HIV-1 DNA decline on ART
One third of the participants recruited to SPARTAC 
were randomised according to the trial proto-
col to receive 48 weeks of ART before under-
taking a treatment interruption (SPARTAC Trial 
Investigators et al., 2013). This allowed us not 
only to study the impact of ART on HIV-1 DNA lev-
els in this cohort (which has been reported in different cohorts [Siliciano et al., 2003; Chun et al., 2007]), 
but also to characterise what happens on stopping therapy after treatment initiated during PHI.
Prior to starting ART, Total and Integrated HIV-1 DNA levels were significantly different (p < 0.0001; 
Students t test) (Figure 3), most likely explained by the presence of unintegrated circular and linear 
DNA forms. As expected, HIV-1 DNA levels after 48 weeks of ART were significantly lower than those 
measured at baseline (p < 0.0001 for all comparisons; Students t test) by 0.63 log copies/million CD4 
cells for Total, and 0.59 log copies/million CD4 cells for Integrated (Figure 3). After 48 weeks of ART, 
Total DNA levels remained significantly greater than Integrated levels in patients despite undetectable 
viraemia (0.027; paired t test) (Figure 3). This is consistent with other reports of residual unintegrated 
HIV-1 DNA up to a year after ART initiation (Agosto et al., 2011).
Having ascertained that in untreated individuals HIV-1 DNA was a predictor of progression, we now 
asked whether the lower HIV-1 DNA levels following ART would predict progression if therapy was 
stopped. This has potentially greater utility, as the majority of individuals on successful ART will have 
undetectable plasma viraemia using standard assays.
HIV-1 DNA at the point of stopping ART predicts clinical progression
We measured DNA levels in participants who received a median of 48 (IQR 47.7–48.7) weeks of ART 
with successfully suppressed viraemia (VL < 50 copies/ml plasma), immediately prior to treatment 
Table 1. Patient demographics
Total participants  
available for analysis*
Number 154
Patients with a Total HIV-1  
DNA test
154 (100%)
Patients with an Integrated  
HIV-1 test
111 (72%)
Log10 baseline Total HIV-1  
DNA copies/ml
3.88 (3.42–4.24)
Log10 baseline Integrated  
HIV-1 DNA copies/ml
3.6 (3.26–3.79)
Time since seroconversion  
(days)
73.82 (49.2–95.8)
Log10 Baseline Viral Load  
copies/ml
4.62 (3.95–5.25)
Baseline CD4 Cell count  
(cells/μl)
558 (428–680.9)
Country of recruitment
 Australia 21 (13.6%)
 Italy 18 (12%)
 Brazil 13 (8.4%)
 UK 102 (66.2%)
Viral Subtype (%) B (100%)
Sex
 Female 4 (3%)
 Male 150 (97%)
Data shown are values (% of non-missing values) for 
categorical data or medians and interquartile ranges in 
brackets for continuous variables.
*At the week 0 ‘baseline’ timepoint’. A subset of these 
patients (Supplementary files 1 and 2) was used for 
analyses at later time-points.
DOI: 10.7554/eLife.03821.003
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interruption. The demographics of the subset of individuals (n = 47) studied in this analysis are detailed 
in Supplementary file 1. Kaplan–Meier survival analyses were undertaken in which participants were 
again divided into two groups (low and high) based on median HIV-1 DNA levels at TI. Both low Total 
and Integrated HIV-1 DNA levels associated with a longer time to trial endpoint (p = 0.039 and 
0.031, respectively; log-rank test) (Figure 4). The median time from TI to primary endpoint stratified 
by low and high Total HIV-1 DNA levels was 159.2 (IQR 111.9–200.6) and 117.8 (IQR 67.8–173.8) 
weeks, respectively, and by low and high Integrated levels was 166 (IQR 124.9–200.6) and 101.1 (IQR 
65.5–156.8) weeks, respectively.
In univariable Cox regression analyses, Total and Integrated HIV-1 DNA both predicted clinical pro-
gression from TI, determined by time to reaching the trial primary endpoint (Total HR 3.52 [1.32–9.37]; 
p = 0.012; Integrated HR 3.01 (1.13–7.95); p = 0.027). Multivariable cox regression models were con-
structed with HIV-1 DNA and CD4 cell count at TI. Viral load was not included as it was undetectable 
at TI. Both Integrated (HR 2.81 CI (1.05–7.55) p = 0.04) and Total (HR 3.42 CI (1.29–9.05) p = 0.013) 
HIV-1 DNA retained significance, and in both cases CD4 T cell count at TI was not a significant pre-
dictor (HR 1.04 CI (0.83–1.11) p = 0.58 and HR 0.94 CI 0.825–1.08 p = 0.4). At TI, HIV-1 DNA was the 
only predictor of the primary end point.
HIV-1 DNA increases on stopping ART
One of the concerns around the viral rebound following a TI is the risk of ‘re-seeding’ the reservoir in 
individuals who might have extremely low HIV-1 DNA levels, and who might be candidates for ‘post-
treatment control’ of viraemia (Hocqueloux et al., 2010). We therefore measured HIV-1 DNA in those 
participants who had received 48 weeks of ART at the point of TI and then again 4, 12 and 60 weeks 
post TI, where samples were available. Total and Integrated HIV-1 DNA levels were not significantly 
Figure 1. HIV-1 DNA correlates with baseline plasma viral load and CD4 T cell count. Pre-therapy ‘baseline’ Total 
HIV-1 DNA (black points and line) (n = 154) and Integrated HIV-1 DNA (n = 111) (red points and line) correlated with 
log10 plasma HIV-1 RNA (A) and CD4 cell count (B).
DOI: 10.7554/eLife.03821.004
The following figure supplements are available for figure 1:
Figure supplement 1. Distribution of log10 total and integrated HIV-1-DNA levels in untreated patients at 
baseline. 
DOI: 10.7554/eLife.03821.005
Figure supplement 2. Pearson correlation for total and integrated HIV-1 DNA levels in untreated patients at 
baseline. 
DOI: 10.7554/eLife.03821.006
Figure supplement 3. Relationship between estimated time since seroconversion and HIV-1 DNA levels. 
DOI: 10.7554/eLife.03821.007
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greater than at the time of ART cessation for up to 12 weeks post TI, although had significantly 
increased 60 weeks after TI (p < 0.0001 for Total and Integrated DNA; Students t test), returning 
approximately to the Week 0 pre-therapy levels (Figure 3). The increase in Total and Integrated 
HIV-1 DNA 4 weeks after TI was not significant (p = 0.30), in contrast to the rebound in plasma virae-
mia (p < 0.001), which may be re-assuring for those implementing a TI strategy in which ART would 
be re-introduced when plasma VL became detectable.
Of note, in an analysis of those individuals who subsequently restarted ART after the TI–and for 
whom we had samples (n = 15)–there was no significant difference between the HIV-1 reservoir size 
pre-TI and at least 6 months after re-starting ART (p = 0.58; paired students t test; Figure 3—figure 
supplement 1), suggesting that any increase in HIV-1 DNA on stopping ART may be reversible if 
therapy is re-commenced. However, larger studies will be needed to confirm these data.
HIV-1 DNA at ART cessation predicts time to plasma viral load rebound
Although almost all participants in SPARTAC experienced VL rebound on stopping ART, we have 
previously shown that of those who received >12 weeks of therapy, 14% still had undetectable virae-
mia 12 months later (Stohr et al., 2013). We therefore wished to establish—albeit in this different, 
although overlapping, sub-group of SPARTAC participants—whether HIV-1 DNA predicted the return 
of plasma viraemia post-TI. As our previous findings included participants in centres using both 50 and 
Table 2. Cox regression models for variables associated with clinical progression in untreated 
individuals followed up from PHI
Univariable unadjusted Multivariable adjusted
Covariate HR (95% CI) p Value HR (95% CI) p Value
Total DNA (log10 DNA copies) 4.16 (2.1–8.26) <0.001 3.57 (1.58–8.08) 0.002
Viral load (log10 RNA copies) 1.74 (1.14–2.67) 0.011 1.25 (0.80–1.95) 0.33
CD4+ T cell count/100 cells 0.66 (0.53–0.82) <0.001 0.67 (0.53–0.84) <0.001
Univariable and multivariable cox regression models were used to determine predictors of clinical progression in 
untreated individuals followed up from Primary HIV-1 Infection. Progression was determined according to reaching 
the SPARTAC trial primary endpoint (Chun et al., 2010). Co-variables analysed were baseline (i.e. first pre-therapy 
trial sample) Total HIV-1 DNA, baseline plasma viral load and baseline CD4+ T cell count.
DOI: 10.7554/eLife.03821.009
Figure 2. HIV-1 DNA predicts clinical progression in absence of ART. Kaplan–Meier survival analyses for (A) Total  
(n = 51) and (B) Integrated (n = 38) HIV-1 DNA and clinical progression, based on time from randomization to the 
SPARTAC trial primary endpoint of a CD4 T cell count of 350 cells/μl or starting long-term ART. HIV-1 DNA data  
was divided into two ‘high’ and ‘low’ at the median level, which was 4.02 and 3.61 copies HIV-1 DNA per million 
CD4 T cells for Total and Integrated, respectively. Significance was determined by log rank test.
DOI: 10.7554/eLife.03821.008
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Figure 3. Analysis of impact on HIV-1 DNA of antiretroviral therapy. Total and Integrated HIV-1 DNA levels and 
plasma viral load (HIV-1 RNA) were measured at Week 0 ‘baseline’ (in participants from all three trial arms prior to 
any therapy) and also in those receiving 48 weeks of ART (weeks 48, 52, 60 and 108 after baseline). DNA levels 
(log10 copies/million CD4 T cells) and viral load (log10 copies/ml plasma) were measured at all time-points, but  
not all participants were sampled at all time-points dependent on sample availability. Significance was determined 
by unpaired Students t Tests or paired t test (marker with *) when samples at the two time-points being compared 
were matched.
DOI: 10.7554/eLife.03821.010
The following figure supplement is available for figure 3:
Figure supplement 1. Impact of stopping and re-starting ART on HIV-1 DNA. 
DOI: 10.7554/eLife.03821.011
400 copies/ml as the lower limit of detection for plasma viral load assays, we studied both cut-offs for 
the HIV-1 DNA analyses.
No patients were censored before viral rebound was detected and all were aviraemic (<50 copies/ml 
plasma) at the point of stopping ART. Levels of Total (but not Integrated) HIV-1 DNA at TI predicted 
time to viral rebound to 400 copies/ml by univariable Cox regression analysis (HR 2.43 (1.23–4.79) 
p = 0.010). CD4 T cell count at TI was not predictive (HR 0.92 (0.78–1.08) p = 0.32) (Supplementary 
file 3). In a multivariable Cox regression model including Total HIV-1 DNA and CD4 count, both sam-
pled at the point of TI, only Total HIV-1 DNA significantly predicted time to viral rebound to 400 copies 
(HR 2.68 [1.31–5.48] p = 0.0069) (Supplementary file 3). When using values from pre-therapy base-
line rather than at the time of TI in the model, neither plasma viral load nor CD4 T cell count predicted 
time to viral rebound (>400 copies/ml) from TI (HR 1.38 [0.96–1.99] p = 0.080) and (HR 1.03 [0.92-1.12] 
p = 0.60), respectively. Kaplan–Meier survival analyses showed similar results, with a low Total HIV-1 
DNA (based on stratification around the median level) associated with a slower time to a viral rebound 
of 400 copies/ml (p = 0.0038; log-rank test) but not to 50 copies per ml (p = 0.18) (Figure 5).
It was unclear why Total HIV-1 DNA should predict rebound to 400 copies but not to 50. In an 
attempt to explain this we studied those individuals with data available at both cut-offs. In this small 
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post-hoc analysis (n = 45), we found that rebound varied according to the HIV-1 DNA level at the time 
of TI. Patients with high Total HIV-1 DNA levels were more likely to have a first detectable VL greater 
than 400 copies/ml, whereas those with lower HIV-1 DNA levels were more likely initially to rebound 
below 400 but above 50 copies/ml (p = 0.0074; Fisher's exact test) (Supplementary file 4). In sum-
mary, we find evidence that HIV-1 DNA is a significant predictor of the duration of viral remission and 
magnitude of the initial rebound following TI. This, if confirmed in larger studies, would have implica-
tions for those designing protocols for ART-reintroduction following viral rebound in TI studies.
Discussion
Since first described nearly two decades ago a persistent reservoir of HIV-1-infected cells remains the 
main reason that HIV-1 infection cannot be cured (Chun et al., 1997; Finzi et al., 1997; Wong et al., 
1997). The simplest measure of the reservoir is a qPCR assay that detects all intracellular HIV-1 DNA 
regardless of whether it is integrated into host chromosomes or is in unintegrated linear or circular 
forms. A modification of this assay incorporates an initial step to prime host Alu repeats in order to 
quantify only viral DNA that has been integrated into host DNA. These assays are open to criticism as 
the vast majority of intracellular HIV-1 DNA is thought to be replication incompetent, and qPCR is not 
able to discriminate between replication competent and incompetent viral DNA genomes. This has 
led to the development of alternative approaches such as viral outgrowth assays (which are considered 
the gold standard, but are expensive and time-consuming, even with recent improvements to their 
protocols [Laird et al., 2013]) and assays to measure intracellular HIV-1 RNA, which may more accu-
rately reflect an infected cell's ability to produce new virions, especially under conditions where viral 
transcription is stimulated (Bullen et al., 2014).
Despite the debate over the biological relevance of measuring HIV-1 DNA—and bearing in mind 
that none of these assays have been standardised for clinical use–a number of reports have attributed 
clinical meaning to HIV-1 DNA assays. Over a decade ago Tierney and colleagues suggested that provi-
ral DNA in PBMCs from 111 participants receiving limited nucleoside analogue therapy was an inde-
pendent predictor of clinical progression, although it is unclear how suppressive the ART regimes were 
in this study (Tierney et al., 2003). Havlir et al studied 100 individuals with chronic HIV-1 infection and 
viral suppression on ART and showed that HIV-1 DNA independently predicted residual viraemia on ART 
(Havlir et al., 2005). However there has not been a comprehensive analysis of both HIV-1 Total and 
Integrated HIV-1 DNA in individuals randomised to treatment or no treatment soon after seroconversion.
Figure 4. HIV-1 DNA on ART predicts clinical progression following treatment interruption. Kaplan–Meier survival 
analyses for (A) Total (n = 47) and (B) Integrated (n = 47) HIV-1 DNA and clinical progression, based on time to the 
SPARTAC trial primary endpoint of a CD4 T cell count of 350 cells/μl or starting back on long-term ART. HIV-1 DNA 
data was divided into ‘high’ and ‘low’ at the median. Significance was determined by log rank test. Participants had 
received a median of 48 weeks of ART and then undertook a treatment interruption. DNA levels were measured at 
week 48, at the point of stopping ART. Time from TI to primary endpoint is plotted on the x-axis.
DOI: 10.7554/eLife.03821.012
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We applied both Total and Integrated DNA measures to a unique cohort of individuals with evi-
dence of PHI randomised to immediate interrupted ART or no therapy with longitudinal follow-up for 
a median of 4.5 years. As participants were randomised to different short course ART therapies prior 
to TI, we were able to determine how well HIV-1 DNA correlated with accepted surrogate markers of 
progression such as VL and CD4 count, and also whether HIV-1 DNA was an independent predictor of 
disease progression within the SPARTAC trial in both treated and untreated participants.
Our first finding that HIV-1 DNA associated closely with both plasma VL and CD4 cell counts (Figure 1) 
was not surprising as this is reported elsewhere (Chun et al., 2010; Parisi et al., 2012). Our findings that 
both baseline and pre-TI HIV-1 DNA strongly predicted the trial primary endpoint (Figure 4 and Table 2) 
are supported by data from other smaller, discrete observational studies, in which low HIV-1 DNA levels 
associated with a longer time to clinical progression (Goujard et al., 2006; Minga et al., 2008; Piketty 
et al., 2010), a lower viral set point and reduced chance of virological failure on ART re-initiation (Yerly 
et al., 2004) at PHI. We are aware of one other report associating HIV-1 DNA with time to viral rebound 
on stopping ART (Yerly et al., 2004). In this study Yerly and colleagues studied chronically-infected indi-
viduals with sequential treatment interruptions and reported that DNA was a predictor of the peak of 
viraemia following therapy cessation and failure to reach undetectable viraemia on re-starting ART–they 
do not report on the actual duration of viral suppression after TI. In a smaller study at PHI, Lafeuillade et al 
also associated HIV-1 DNA with time to rebound, however this study is complicated by other interventions 
such as IL-2 and hydroxyurea in addition to ART (Lafeuillade et al., 2003).
Figure 5. HIV-1 DNA at ART interruption predicts time to viral rebound. Survival analyses of time to viral rebound 
(weeks) in participants undertaking TI after 48 weeks of ART. HIV-1 DNA levels are presented divided at the median 
level into high (red) and low (black). Rebound to 400 HIV-1 RNA copies (n = 46) is presented for Total (A) and 
Integrated (B) HIV-1 DNA. Rebound to 50 HIV-1 RNA copies (n = 45) is presented for Total (C) and Integrated  
(D) HIV-1 DNA. Significance was determined by log rank test.
DOI: 10.7554/eLife.03821.013
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We measured plasma viral load in the pre-therapy ‘baseline’ sample closest to the estimated time 
of infection. One possible criticism—and explanation for why plasma VL was less predictive in this 
study—is that other studies have associated progression with the ‘set-point’ viral load, the value at 
which the VL stabilizes following the dynamic PHI stage. However, in our untreated participants we 
found that the ‘baseline’ and ‘set-point’ VL values were highly correlated, although the former was 
higher, as would be expected (data not shown). From a clinical perspective, it is worth noting that if 
individuals with PHI are commenced on ART immediately, then their ‘set-point’ VL will not be known, 
potentially placing greater impact on the less dynamic HIV-1 DNA measure.
After TI, we observed a period of at least 12 weeks where no significant increases in the HIV-1 reser-
voir level were detected by both assays (Figure 3). However, we found little evidence of longer term 
post-treatment control (Persaud et al., 2013; Saez-Cirion et al., 2013), as levels of HIV-1 DNA 1-year 
after therapy interruption were not significantly different to that seen at pre-therapy baseline. 
Nevertheless, the potential for there to be a short window period during which plasma viraemia has 
rebounded but HIV-1 DNA levels have not risen significantly is encouraging, if future closely-monitored 
TI studies are to be undertaken. Concerns around ‘re-seeding’ the reservoir are very real, and it is impor-
tant that any possible harm associated with a TI is limited. It is therefore also re-assuring that in our 
admittedly small sub-study, re-initiation of ART subsequently restored HIV-1 DNA to pre-TI levels.
Finally, a low ‘Total’ HIV-1 reservoir at TI resulted in a longer time to a viral rebound to 400 copies/ml 
(Figure 5). In univariable and multivariable Cox regression models Total HIV-1 DNA at TI predicted 
time to rebound to 400 copies/ml, whereas CD4 T cell count did not (Supplementary file 3). Of 
interest, the baseline VL and CD4 prior to therapy were also not predictive of time to rebound. In 
contrast to other studies exploring TI, we have a larger and randomly allocated patient group who 
have received similar durations of ART at PHI and hence can be directly compared. Although viral 
rebound was observed in all individuals after TI ultimately, this is the first report of a randomised 
cohort that has shown that time to viral rebound and primary study end point could be predicted by 
HIV-1 DNA measurement at TI.
Our findings of an association with HIV-1 DNA and time to viral rebound raise a number of other 
questions. Why was Total DNA predictive of rebound but not Integrated? Why was Total DNA pre-
dictive for rebound to 400 copies/ml but not 50 copies/ml? Much larger studies will be needed to 
answer most of these questions, however our sub-analysis of rebounding patients suggested that a 
high Total DNA at TI was more indicative of a higher VL rebound (i.e. >400 copies), whereas a low 
DNA level was not associated with a lower rebound. These data might indicate that a Total DNA level 
at TI is better at predicting the patients who will be quick to rebound rather than those who will main-
tain suppression. A question for larger studies to answer will be to define what the viral load cut-off 
should be for considering rebound, rather than just assuming the assay with the lowest limit of detec-
tion is best. Data from at least one other study (Riabaudo et al., 2009) indicate that a level greater 
than 50 copies/ml may be more relevant. The difference between the Integrated and Total DNA is also 
interesting. Integrated DNA should be the most biologically relevant marker, based on the assumption 
that unintegrated HIV-1 DNA forms are thought not to contribute to rebound viraemia. However, the 
assay for Total HIV-1 DNA is much simpler and with tighter coefficients of variation, possibly due to the 
lack of a pre-amplification PCR stage. Another important factor impacting our data is that the median 
estimated time from seroconversion was 73.8 days, and so most of our patients would be starting 
therapy at Fiebig stage IV or later. It is possible that earlier identification of PHI and initiation of ART 
would have a greater impact on the reservoir and post-treatment control, and it is important that 
large studies are undertaken to determine this.
In light of observational cohorts such as VISCONTI (Saez-Cirion et al., 2013) where treatment ces-
sation revealed individuals who remain aviraemic post TI, there is increasing interest in undertaking 
closely monitored treatment interruption studies in which ART would be re-started based on a detect-
able plasma VL. These do not, however, have an encouraging history with previous studies set in the 
context of therapeutic vaccination or CD4 T cell restoration, resulting in rapid viraemic rebound and 
even harm (Strategies for Management of Antiretroviral Therapy (SMART) Study Group et al., 
2006; Angel et al., 2011; Garcia et al., 2013). Additionally, the recent report of viral rebound in the 
case of the Mississippi baby, means that greater understanding of mechanisms behind post-treatment 
control is needed. The potential, therefore, to develop an algorithm to combine various biomarkers to 
help predict individuals suitable for such studies is appealing. These data are evidence that such an algo-
rithm may be possible, and that a marker as simple as HIV-1 DNA could be an important component.
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Materials and methods
Participants and trial design
The design of the SPARTAC trial is reported elsewhere (SPARTAC Trial Investigators et al., 2013). 
In brief, SPARTAC was an international open Randomised Controlled Trial enrolling adults with PHI within 
6 months of a last negative, equivocal or incident HIV-1 test. All participants gave written informed 
consent. Research ethics committees in each country approved the trial. Time of seroconversion was esti-
mated as the midpoint of last negative/equivocal and first positive tests, or date of incident test. Participants 
were randomised to receive ART for 48 weeks (ART-48), 12 weeks (ART-12) or no therapy (standard of care, 
SOC). The primary endpoint was a composite of two events: if participants either reached a CD4 count of 
<350 cells/mm3 (>3 months after randomization and confirmed within 4 weeks) or initiated long-term ART. 
This provided an immunological surrogate of clinical progression, but also allowed inclusion of those 
participants who commenced ART at CD4 cell counts greater than 350 cells/mm3. Time to virological 
failure of participants randomized to ART-48 (two analyses using both 50 and 400 HIV-1 RNA copies/ml 
as the cut-off [two consecutive readings]) was a secondary endpoint.
Participants for this sub-study of SPARTAC were those infected with subtype B HIV-1 and for whom 
adequate samples were available. For those in the analysis of progression and viral rebound at TI, we only 
selected participants who had viral load suppression (<50 copies/ml; Chiron bDNA) at point of stopping 
ART (Table 1 and Supplementary file 1). CD4 T cells isolated from peripheral blood mononuclear cells 
(PBMC) were sampled for HIV-1 DNA in all participants at baseline, regardless of trial arm. Participants 
randomised to the ART-48 arm were sampled at week 48 at the point of stopping ART and at a further 4, 
12 and 60 weeks post ART interruption (52, 60 and 108 weeks post-ART initiation). Participants who were 
viraemic using the Chiron bDNA, (Bayer, Leverkusen, Germany) (LLD 50 copies/ml) at the point of TI were 
excluded.
Measurement of HIV-1 DNA
CD4 T cells were enriched from frozen PBMC samples by negative selection (Dynabeads, Invitrogen, 
Carlsbad, CA) to a purity of >97%. CD4 T cell DNA was extracted (Qiagen, Venlo, Netherlands) and 
used as input DNA for PCR. Cell copy number and total HIV-1 DNA levels were quantified both in 
triplicate using previously published assays (Duncan et al., 2013; Jones et al., 2014).
Integrated HIV-1 was measured using an assay based on that previously published (Liszewski et al., 
2009) but with some minor modifications. 40 repeated integration measurements per patient sample 
were performed along with five PCR reactions to which no Alu primer was added, to serve as a back-
ground control for determination of sample positivity. The first round master mix contained 1.5 U 
platinum taq per 50 µl reaction. The second round qPCR reaction was the same as the Total reaction 
described above, but with 10 µl of first round product being the input DNA.
To quantify patient samples, one standard curve was generated by plotting the average cycle 
threshold (Ct) values for all integration signals at each Integration Standard (IS) dilution (70–0.2 copies 
of IS standard per well, diluted in 2 µg/ml PBMC DNA), so long as at least one integration signal was 
significantly different (two standard deviations) to the average gag-only background signal. The IS was 
a kind gift from Una O’Doherty. Ln(Copy number) was plotted vs Ln(average Ct) and each point on the 
standard curve was repeated in duplicate. The standard curve fitted extremely well to a line of best fit 
(r2 = 0.987), which was then used to calculate copy numbers in patient samples. Each patient sample 
replicate was quantified individually using the standard curve to generate error. Plate to plate variation 
was assessed using quadruplicate replicates of 8e5 cells, which have one copy of HIV-1 per cell, diluted 
to 100 copies per well as a first round PCR DNA input. The average coefficient of variance was 8.31%.
Statistical analysis
HIV-1 DNA (Total and Integrated) distributed normally following log10 transformation. The association 
between Total and Integrated HIV-1 DNA levels was tested using Pearson correlations. Linear regres-
sion was used to examine the association between continuous clinical baseline covariates and HIV-1 
DNA. Tests between grouped variables and DNA levels were tested with Mann–Whitney, Kruskal–
Wallis and t tests where appropriate.
For the association between baseline DNA and the SPARTAC primary endpoint, Kaplan–Meier plots 
and univariable Cox models were constructed, and subsequently adjusted for baseline covariates. 
Where participants received ART, the time to primary endpoint was calculated from the time of TI. 
Human biology and medicine | Microbiology and infectious disease
Williams et al. eLife 2014;3:e03821. DOI: 10.7554/eLife.03821 12 of 16
Research article
Association with time to rebound was also assessed using Kaplan–Meier plots and Cox models. All 
statistics were calculated using R version 3.1.0. Plots were drawn using Prism version 5.0.
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randomised to receive either no therapy from PHI (first column) and those randomised to receive 48 
of weeks of ART from PHI (second column). Data as indicated were: † determined at pre-therapy 
baseline (trial week 0), * determined at week 48, prior to TI or + median (interquartile range). SOC: 
Standard of Care trial arm.
DOI: 10.7554/eLife.03821.014
• Supplementary file 2. Sample numbers available at each time-point by trial randomization. Numbers 
of samples available at each time-point are presented. Participants from all three trial arms were 
included at week 0 as they were all treatment naïve at this point. Not all patients at any one time-point 
are always represented at other time-points due to variation in sample availability. Trial arms: SOC: 
Standard of Care (untreated); ART-48: 48 weeks of ART after randomization; ART-12: 12 weeks of ART 
after randomization.
DOI: 10.7554/eLife.03821.015
• Supplementary file 3. Cox regression models for variables associated with time to rebound of 
400 copies/ml and sampled at wk48. Table to show results of Cox regression analysis for time to 
virological rebound of 400 copies/ml of plasma with Total DNA and CD4 T cell count as covariables. 
Univariable and multivariable data are presented with Hazard Ratios (HR) with 95% Confidence 
Intervals (CI) and associated P values.
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• Supplementary file 4. 2 × 2 table comparing the number of patients with different times to 50 and 
400 copy/ml rebound and their total and integrated pre-TI HIV-1 DNA levels. Table to compare the 
association between HIV-1 DNA levels at TI (both Total and Integrated) and time to a plasma viral load 
of either between 50–400 copies/ml or greater than 400 copies/ml. HIV-1 DNA levels were split into 
‘high’ and ‘low’ by the median value. The proportions are significantly different by Fisher's exact test 
for Total (p = 0.0074) but not Integrated HIV-1-DNA levels (p = 0.091).
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